{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:00Z","timestamp":1789603800677,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Our study aimed to investigate the prevalence and demographic characteristics of immune checkpoint inhibitor-associated primary adrenal insufficiency (ICI-PAI) and to explore the risk factors of its clinical outcome using data from the US FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective study. All cases of new-onset or newly diagnosed primary adrenal insufficiency associated with FDA-approved ICIs from 1 January 2007 to 31 December 2020 were identified and collected using FAERS. Data on age, sex category, body weight of the participating individuals, the reporting year and the prognosis of cases, and other accompanying endocrinopathies related to ICIs, were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of ICI-PAI was 1.03% (1180\/114121). Of the 1180 cases of PAI, 46 were \u201cconfirmed PAI\u201d, and 1134 were \u201csuspected PAI\u201d. Combination therapy with anti-CTLA-4 and anti-PD-1 was related to a higher risk of PAI compared with the anti-PD-1-only group (\u03c7<jats:sup>2<\/jats:sup>\u2009=\u200992.88, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Male and elderly individuals showed a higher risk of ICI-PAI (male vs. female, 1.17% vs. 0.94%, <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200912.55, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; age\u2009&lt;\u200965 vs.\u2009\u2265\u200965, 1.20 vs. 1.41%, <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20096.89, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). The co-occurrence rate of endocrinopathies other than PAI was 24.3%, which showed a higher trend in patients on nivolumab-ipilimumab treatment than in those on PD-1 inhibitors (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20093.227, <jats:italic>p<\/jats:italic>\u2009=\u20090.072). Body weight was negatively associated with the risk of death in the study population [<jats:italic>p<\/jats:italic>\u2009=\u20090.033 for the regression model; B\u2009=\u2009\u2013\u00a00.017, OR 0.984, 95% CI (0.969\u20130.998), <jats:italic>p<\/jats:italic>\u2009=\u20090.029].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ICI-associated PAI is a rare but important irAE. Male and elderly patients have a higher risk of ICI-PAI. Awareness among clinicians is critical when patients with a lower body weight develop PAI, which indicates a higher risk of a poor clinical outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01845-z","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T13:03:50Z","timestamp":1658581430000},"page":"2131-2137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS"],"prefix":"10.1007","volume":"45","author":[{"given":"D.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-8900","authenticated-orcid":false,"given":"Y.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"issue":"17","key":"1845_CR1","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) National comprehensive cancer network management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"2","key":"1845_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173\u2013182","journal-title":"JAMA Oncol"},{"issue":"3","key":"1845_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","volume":"3","author":"I Bancos","year":"2015","unstructured":"Bancos I, Hahner S, Tomlinson J et al (2015) Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 3(3):216\u2013226","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1845_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM et al (2017) Cancer immunotherapy- immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195\u2013207","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1845_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","volume":"30","author":"JC Yang","year":"2007","unstructured":"Yang JC, Hughes M, Kammula Y et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30(8):825\u2013830","journal-title":"J Immunother"},{"key":"1845_CR6","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0108","author":"H Traner","year":"2016","unstructured":"Traner H, Hulse P, Higham CE et al (2016) Hyponatremia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-16-0108","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"issue":"3","key":"1845_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70031-7","volume":"1","author":"L Min","year":"2013","unstructured":"Min L, Ibrahim N (2013) Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 1(3):e15","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1845_CR8","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"24","author":"P Cukier","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M et al (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24(12):T331\u2013T347","journal-title":"Endocr Relat Cancer"},{"key":"1845_CR9","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1002\/cam4.2661","volume":"8","author":"J Lu","year":"2019","unstructured":"Lu J, Li L, Lan Y et al (2019) Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis. Cancer Med 8:7503\u20137515","journal-title":"Cancer Med"},{"key":"1845_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","volume":"25","author":"V Grouthier","year":"2020","unstructured":"Grouthier V, Lebrun-Vignes B, Moey M et al (2020) Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis. The Oncologists 25:696\u2013701","journal-title":"The Oncologists"},{"issue":"8","key":"1845_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102590","volume":"19","author":"P Triggianese","year":"2020","unstructured":"Triggianese P, Novelli L, Galdiero MR et al (2020) Immune checkpoint inhibitors-induced autoimmunity: the impact of gender. Autoimmun Rev 19(8):102590","journal-title":"Autoimmun Rev"},{"key":"1845_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai Y, Ye X, Hu F et al (2019) Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system. J Immuno Therapy Cancer 7:286","journal-title":"J Immuno Therapy Cancer"},{"key":"1845_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226","journal-title":"BMJ"},{"issue":"1","key":"1845_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","volume":"19","author":"X Sun","year":"2019","unstructured":"Sun X, Roudi R, Dai T et al (2019) Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 19(1):558","journal-title":"BMC Cancer"},{"issue":"14","key":"1845_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni C, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356","journal-title":"N Engl J Med"},{"issue":"3","key":"1845_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud-Coffin","year":"2019","unstructured":"Arnaud-Coffin P, Maillet D, Gan HK et al (2019) A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 145(3):639\u2013648","journal-title":"Int J Cancer"},{"issue":"1","key":"1845_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","volume":"33","author":"L Martin","year":"2015","unstructured":"Martin L, Senesse P, Gioulbasanis I et al (2015) Diagnostic criteria for the classification of cancer- associated weight loss. J Clin Oncol 33(1):90\u201399","journal-title":"J Clin Oncol"},{"key":"1845_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583\u2013589","journal-title":"Ann Oncol"},{"key":"1845_CR19","volume":"19","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH et al (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Onco Immunol 19:e1375642","journal-title":"Onco Immunol"},{"key":"1845_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216954","volume":"14","author":"I Yamauchi","year":"2019","unstructured":"Yamauchi I, Yasoda A, Matsumoto S et al (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE 14:e0216954","journal-title":"PLoS ONE"},{"key":"1845_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ando.2017.12.001","volume":"79","author":"Y Reznik","year":"2018","unstructured":"Reznik Y, Barat P, Bertherat J et al (2018) SFE\/SFEDP adrenal insufficiency French consensus: introduction and handbook. Ann Endocrinol (Paris) 79:1\u201322","journal-title":"Ann Endocrinol (Paris)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01845-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01845-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01845-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T06:18:40Z","timestamp":1664518720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01845-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01845-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All cases in the study were anonymous, all data are available from public resources, and the requirement for informed consent and ethical approval was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}